Trial Profile
A phase 2 study of oral apabetalone in hospitalized subjects with Covid-19 infection
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Apabetalone (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 09 Nov 2021 New trial record
- 01 Nov 2021 According to a Resverlogix Corporation media release, the company is in active discussions with the Kingdom of Morocco's Ministry of Health for possible Phase 2 COVID-19 clinical studies for Apabetalone, under the leadership of Professor Bouchra Meddah, Director of Medicines and Pharmacy.